NDA 217722

NDA APPROVAL

Harm Reduction Therapeutics, Inc.
Attention: Thomas (Tom) Huijbers
Regulatory Affairs
4800 Montgomery Lane, Suite 400
Bethesda, MD 20814

Dear Mr. Huijbers:

Please refer to your new drug application (NDA) dated and received on October 28, 2022, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for RiVive (naloxone hydrochloride) nasal spray, 3 mg/0.1 mL.

We acknowledge receipt of your major amendment dated February 17, 2023, which extended the goal date by 3 months.

This new drug application provides for the use of RiVive (naloxone hydrochloride) nasal spray, 3 mg/0.1 mL, for emergency treatment of opioid overdose.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling described in the table below and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

Proposed Draft Labeling	**Date Submitted**
Drug-Delivery Device Label (Front)	June 6, 2023
Drug-Delivery Device Label (Back)	June 6, 2023
Immediate Container (Blister Package) Label	June 6, 2023
Package Insert	June 23, 2023
2-Count Outer Carton	July 6, 2023

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD*

Specifications (February 2020).[1] For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 217722**." Approval of this submission by FDA is not required before the labeling is used.

If you are interested in marketing other package configurations in the future (e.g., package sizes containing fewer than two doses), a prior approval supplement that includes data to adequately demonstrate appropriate consumer comprehension of use must be submitted. We encourage you to contact us about the content and format of such a supplement prior to submission.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for RiVive (naloxone hydrochloride) nasal spray, 3 mg/0.1 mL, shall be 36 months from the date of manufacture when stored between 20°C to 25°C (68°F to 77°F).

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.[2] Information on submitting SPL files using eLIST may be found in the draft guidance for industry *SPL Standard for Content of Labeling Technical Qs & As* (October 2009).[3] In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

---

[1] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

[2] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

[3] When final, this guidance will represent the FDA's current thinking on this topic.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

This product is appropriately labeled for use in all relevant pediatric populations; therefore, no additional pediatric studies are needed at this time.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at FDA.gov.[4]

If you have any questions, call CDR Trang Tran, Senior Regulatory Project Manager, at (240) 402-7945, or email at Trang.Tran@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Nushin Todd, MD, PhD
Director
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Carton, Container, and Package Insert Labeling

[4] https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NUSHIN F TODD
07/28/2023 10:51:30 AM